Merck Serono and Quintiles have announced an exclusive five-year clinical development agreement. Quintiles will be the sole primary provider of Merck Serono’s outsourced clinical development services for its global clinical programs. Leaders from Quintiles will collaborate in strategic decision-making processes affecting the development of the Merck Serono portfolio.
Under this agreement, Merck Serono will shape and lead the strategy of its clinical development programs, with Quintiles directing clinical trial planning and execution. Quintiles also will be a key contributor to Merck Serono’s future clinical trial design activities.
“By combining the strengths of Merck Serono and Quintiles, we are creating a new model in clinical development that will unlock the knowledge and insights of both companies,” says Annalisa Jenkins, Executive Vice President and Head of Global Development and Medical at Merck Serono. “This is an innovative and unique collaboration that will help to translate the highest-quality science into efficiency and agility throughout our clinical trials, while enhancing our competitive position in an increasingly challenging environment of clinical drug development.”